文献速递胸部肿瘤放疗

IV期小细胞肺癌的巩固性胸部放疗:欧洲IASLC与ESTRO专家的患者选择

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.
PubMed 文献 · Radiother Oncol · 2019-03-15

研究收集13名IASLC欧洲肿瘤内科医生与13名ESTRO欧洲放射肿瘤科医生的决策策略,构建决策树分析不同参数组合下推荐巩固性胸部放疗的频率。与推荐相关的因素包括患者体能状态、有限胸外肿瘤负荷、初始胸部 bulky 病变及化疗反应;体能状态良好、胸外负荷有限且初始胸部 bulky 病变并达到胸外完全缓解或胸部部分缓解者共识最高(92%推荐)。体能状态差或化疗总体反应差者多数不推荐。

要点

  • 体能状态良好、胸外肿瘤负荷有限且化疗有效的IV期小细胞肺癌患者推荐巩固性胸部放疗共识最高(92%)。
  • 初始胸部 bulky 病变且胸外完全缓解或胸部部分缓解是推荐巩固性胸部放疗的相关因素。
  • 体能状态差或化疗总体反应差的患者,多数专家不推荐巩固性胸部放疗。

核心结论

  • 欧洲肺癌领域的放射肿瘤科与肿瘤内科医生推荐对经选择的IV期小细胞肺癌患者行巩固性胸部放疗,并主要限于化疗有效且胸外肿瘤负荷有限的体能状态良好患者。

研究设计与样本

  • 从国际肺癌研究协会(IASLC)获取13名欧洲肿瘤内科医生名单,从欧洲放射肿瘤治疗学会(ESTRO)获取13名欧洲放射肿瘤科医生名单,收集其IV期小细胞肺癌巩固性胸部放疗的决策策略并构建决策树。
  • 基于客观共识方法分析不同参数组合下推荐巩固性胸部放疗的频率。

主要发现

  • 与推荐巩固性胸部放疗相关的因素包括患者体能状态、有限胸外肿瘤负荷、初始胸部 bulky 病变及化疗反应。
  • 体能状态良好、胸外肿瘤负荷有限且初始胸部 bulky 病变并达到胸外完全缓解或胸部部分缓解时推荐巩固性胸部放疗的共识最高(92%推荐)。
  • 在上述患者中,肿瘤内科医生与放射肿瘤科医生的推荐一致。
  • 在胸内和胸外均为部分缓解且无初始胸部 bulky 病变的情况下,放射肿瘤科医生比肿瘤内科医生更倾向于推荐巩固性胸部放疗。
  • 对于体能状态差或化疗总体反应差的患者,多数专家不推荐巩固性胸部放疗。

关键数值与推荐

  • 体能状态良好、胸外肿瘤负荷有限、初始胸部 bulky 病变且胸外完全缓解或胸部部分缓解的患者中,92%推荐巩固性胸部放疗。
  • 胸内和胸外均为部分缓解且无初始胸部 bulky 病变时,放射肿瘤科医生比肿瘤内科医生更倾向于推荐巩固性胸部放疗。
  • 体能状态差或化疗总体反应差的患者中,多数不推荐巩固性胸部放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of consolidative thoracic radiotherapy (TRT) in stage IV small cell lung cancer (SCLC) is not uniformly accepted. METHODS: We obtained a list of 13 European medical oncologists from the International Association for the Study of Lung Cancer (IASLC) and 13 European radiation oncologists from the European Society for Therapeutic Radiation Oncology (ESTRO). The strategies in decision making for TRT in stage IV SCLC were collected. Decision trees were created representing these strategies. Frequencies of recommending TRT were analysed for various parameter combinations based on the objective consensus methodology. RESULTS: The factors associated with the recommendation for TRT included fitness of the patient, limited extrathoracic tumour burden, initial bulky thoracic disease and response to chemotherapy. The highest consensus for TRT was in fit patients with limited extrathoracic tumour burden and initial bulky disease with either a complete extrathoracic response or partial thoracic response (92% recommend TRT). For these patients the recommendations were the same for medical and radiation oncologists. In the setting of partial response (intra- and extra-thoracically) without initial bulky thoracic disease radiation oncologists were more likely to recommend TRT than medical oncologists. For unfit patients or for patients with poor overall response to chemotherapy, the majority did not recommend TRT. CONCLUSION: European radiation and medical oncologists specializing in lung cancer recommend TRT in selected patients with stage IV SCLC and restrict its use primarily to fit patients who responded to chemotherapy with limited extrathoracic tumour burden.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Putora PM, Glatzer M, De Ruysscher D, et al. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiother Oncol. 2019. PMID: 31015173. doi:10.1016/j.radonc.2019.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。